GTx Estrogen Agonist For Prostate Cancer Looks Effective At Low Doses
This article was originally published in The Pink Sheet Daily
Executive Summary
On the rebound after venous embolisms led to a clinical hold, Capesaris is getting good results at a significantly lower dose than what was used in that fated trial, and GTx is betting the novel estrogen receptor agonist can improve on the efficacy of androgen deprivation therapy while ameliorating its symptoms.
You may also be interested in...
GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path
Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.
GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path
Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.
GTx Muscle Wasting Drug Fails, But Data Offer Possible New Path
Enobosarm failed under FDA analysis plan but met European requirements in NSCLC muscle wasting trials, while a potential survival signal may lead to a positive change of plans in the U.S.